ArticleBMC pharmacology & toxicology2026
Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveConcerns regarding neuropsychiatric adverse events (NPAEs), including depression and suicidality, have emerged with the expanding use of GLP-1-based therapies across metabolic and weight-management indications. This study aimed to characterize neuropsychiatric adverse-event reporting patterns for GLP-1-based therapies in VigiBase using disproportionality analysis.
methodsIndividual case safety reports entered into the WHO global pharmacovigilance database (VigiBase) from inception through 31 January 2025 were examined. Disproportionality analysis using the information components and the reporting odds ratio was conducted to identify putative safety signals. The full VigiBase reporting background during the study period was used as the comparator. We described the drug-event pairs, mapped signal overlap across agents, evaluated the relationship between reporting frequency and signal magnitude, and conducted stratified analyses by sex and age.
resultsAmong 899 280 GLP-1RAs-related reports, 19 811 (2.2%) related NPAEs comprised 273 preferred terms and generated 69 positive signals. Semaglutide and liraglutide presented the broadest and most potent signal portfolios, driven chiefly by binge eating (semaglutide, IC₀₂₅ = 3.379; ROR₀₂₅ = 14.483), and aversion (liraglutide, IC₀₂₅ = 3.365; ROR₀₂₅ = 20.512). In contrast, albiglutide was essentially signal negative, and dulaglutide and tirzepatide generated narrower spectra. In addition, semaglutide was positively associated with two "suicide/self-injury" AEs: "depression suicidal" (ROR₀₂₅ = 4.822) and "suicidal ideation" (ROR₀₂₅ = 2.643).
conclusionsThis study identified several potential drug safety signals. However, the estimates were unadjusted and may be influenced by confounding by indication, channelling, notoriety bias, and event competition. Eating-related signals should be interpreted cautiously because they may overlap with the treated population and appetite-related pharmacology of these agents. Given the spontaneous reporting nature of VigiBase, these findings should be interpreted as potential reporting signals rather than evidence of causality. Further well-designed observational studies and prospective clinical investigations are needed to clarify whether GLP-1-based therapies are associated with increased neuropsychiatric risk and to identify patient-level risk modifiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.